MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid…
24-month overall survival rate of 67 percent achieved with talquetamab 0.8mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study1 BEERSE,…
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA, June 13, 2024 /PRNewswire/ --…
Google executive brings more than two decades of financial and management expertise to medical technology leader's Board CARLSBAD, Calif., June…
LONDON, June 13, 2024 /PRNewswire/ -- The Chopra Foundation and Human Longevity, Inc. (HLI) today announced a groundbreaking partnership to…
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, June…
CHICAGO, IL / ACCESSWIRE / June 13, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and…
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors…
- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model -- Data…